Scilex Holding Company · NASDAQ:SCLX
Scilex — SPAC Merger (March 2022)
21 slides from Scilex's SPAC merger presentation, Mar 18, 2022
Slide 1: Innovative Leader in Non-Opioid Pain Therapeutics
Innovative Leader in Non-Opioid Pain Therapeutics (March 2022)
Slide 2: Safe Harbor Statements
Safe Harbor Statements Forward-Looking Statements Certain statements contained in this corporate presentation (this “Presentation”), along with certain statements that may be made by management of Scilex Holding Company (together with its subsidiaries, “Scilex”) orally in presenting this material, a
Slide 3: Safe Harbor Statements
Safe Harbor Statements Forward-Looking Statements undertakes no obligation to update publicly or revise any forward-looking statements for any reason after the date of this Presentation or to conform these statements to actual results or to changes in Scilex’s expectations. Industry and Market Data
Slide 4: Safe Harbor Statements
Safe Harbor Statements Forward-Looking Statements Investors and security holders of the SPAC are urged to read these materials (including any amendments or supplements thereto) and any other relevant documents in connection with the transaction that the SPAC files with the SEC when, and if, they bec
Slide 5: Safe Harbor Statements
Safe Harbor Statements Forward-Looking Statements Scilex and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of the SPAC in connection with the Proposed Business Combination. Information about Scilex’s directors and exec
Slide 6: Agenda
Agenda Company Overview / Investment Highlights ZTlido Best-in-Class Profile SP-102 (SEMDEXA) Potential First-in-Class for Lumbar Radicular Pain / Sciatica – Path to Approval SP-103 (3X ZTlido) for Low Back Pain SP-104 DBR Low Dose Naltrexone (LDN) for Fibromyalgia Company Summary 6
Slide 7: Best-in-Class Non-Opioid Pain Therapeutics
Best-in-Class Non-Opioid Pain Therapeutics Phase3 Platform Program IND Phase 1 Phase 2 Pivotal NDA Approved Upcoming Milestones ZTlido® 1.8% (Postherpetic Launched US October 2018 Neuralgia-PHN) SP-102 (SEMDEXA) (Lumbar Radicular / Highly significant positive Non-Opioid Sciatica Pain) results from p
Slide 8: Scilex Pipeline – Business Opportunity Highlights
Scilex Pipeline – Business Opportunity Highlights • In the U.S., 50m patients live with chronic pain – A billion adults suffer from acute or chronic pain globally1 • With the opioid pandemic, medical community and regulatory agencies are seeking non-opioid pain options • Scilex offers broad, diverse
Slide 9: Accomplished Executive Team
Accomplished Executive Team Name Position(s) Experience 25+ years of management experience in large Pharma and Biotech Jaisim Shah CEO & President Lead commercialization of multiple blockbusters Rituxan®, Abilify®, Pegasys®, Tequin CEO, Semnur Pharma; CBO, Elevation; CBO, PDL BioPharma; VP, Br
Slide 10: Investment Highlights
Investment Highlights Scilex Holding Company (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), and Vickers Vantage Corp I (Nasdaq: VCKA) signed a merger agreement for the Proposed Business Combination, which provides for a pre-transaction equity value of Scilex of approximately
Slide 11: ZTlido – Best in Class Lidocaine Patch - Revenues Continue to Grow at 30%+ Annually
ZTlido – Best in Class Lidocaine Patch - Revenues Continue to Grow at 30%+ Annually Superior non-aqueous transdermal technology allows for better delivery of lidocaine, improved adhesion and thinner patch – weight 2 gms vs 14 gms for Lidoderm and its follow-ons Supplemental ZTlido sNDA approved
Slide 12: ZTlido YTD Sales Performance Comparison
ZTlido YTD Sales Performance Comparison ZTlido Gross Sales 2021 vs 2020 $65.0 +32% ∆ $50.0 $40.0 $30.0 $63.9MM $20.0 $48.3MM $10.0 $0.0 2020 2021 12
Slide 13: Epidural Steroid Injections One of the Most Common Medical Procedures
Epidural Steroid Injections One of the Most Common Medical Procedures and Top Pain Procedure in the U.S. Common Surgical Strong Growth Rate, Evidenced by Procedures (thousands) (1) Medicare Procedure Volumes Epidural Steroid Injections 12,000 1 All cardiacinterventions 7,500 Operations of the GIsyst
Slide 14: U.S. Market Size—Epidural Steroid Injection (2010-2022)
U.S. Market Size—Epidural Steroid Injection (2010-2022) 14
Slide 15: SP-102 (SEMDEXA) – First in Class Treatment - LRP / Sciatica
SP-102 (SEMDEXA) – First in Class Treatment - LRP / Sciatica • Product Concept – Preservative, surfactant and Phase 3 SP-102 C.L.E.A.R Trial – Primary Endpoint particulate free extended local effect viscous gel formulation product providing durable pain relief for sciatica (subacute lumbosacral radi
Slide 16: C.L.E.A.R. Trial – Key Secondary Endpoint
C.L.E.A.R. Trial – Key Secondary Endpoint The Oswestry Disability Index (ODI) - gold standard for measuring degree of disability and estimating quality of life. Highly statistically significant result for SEMDEXA over placebo. ODI contains 10 topics concerning intensity of pain, lifting, ability to
Slide 17: Phase 3 SP-102 C.L.E.A.R. Trial - Conclusions
Phase 3 SP-102 C.L.E.A.R. Trial - Conclusions The trial met primary, key secondary and other secondary endpoints with high statistical significance over placebo Achieved all study objectives supporting first-in-class efficacy and safety results Demonstrated clear safety profile of SP-102 Next
Slide 18: SEMDEXA – Broad Potential for Life Cycle Management
SEMDEXA – Broad Potential for Life Cycle Management Physicians indicated there is potential opportunity for spontaneous use of SEMDEXA outside of lumbar radiculopathy which could represent an additional upside of ~50-200%* over LR Additional Potential Uses Carpel Tunnel Hip and Knee Replacements
Slide 19: SP-103 Phase 2
SP-103 is a Next-Generation, Triple Strength Formulation of ZTlido 1.8% Tartgeting the Low Back Pain Opportunity SP-103 Phase 2 Next-Generation, 5.4% Lidocaine Topical System Superior adhesion and drug formulation efficiency with 3x drug load (108 mg vs 36 mg lidocaine) only 36mg of lidocaine
Slide 20: Summary of Post Business Combination Plans
Summary of Post Business Combination Plans Clinical development and CMC activities Manufacture of clinical supplies for SP-103 and SP-104, commercial manufacturing for SP-102 Advance SP-103 and SP-104 in U.S. Phase 2/3 clinical trials Pursue ex-U.S. development for our pipeline via strategic p
Slide 21: Scilex Holding Company Summary
Scilex Holding Company Summary Commercial non-opioid pain management company with 3 clinical non- opioid programs in large markets with very high unmet need Launched rapidly growing ZTlido (lidocaine topical system 1.8%)in 2018 with in-house commercial and sales team Semnur Pharma merged with Scilex